CYTEK BIOSCIENCES, INC. Financials Cytek Biosciences, Inc.
Equities
CTKB
US23285D1090
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.76 USD | +2.31% |
|
-2.70% | -36.84% |
| Mar. 20 | Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing | MT |
| Mar. 19 | Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,182 | 1,377 | 1,236 | 756.1 | - | - |
| Enterprise Value (EV) 1 | 1,818 | 1,038 | 975.4 | 535.3 | 521.2 | 490.6 |
| P/E ratio | 326 x | 511 x | -101 x | -160 x | 65.5 x | 41.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 17.1 x | 8.39 x | 6.39 x | 3.64 x | 3.06 x | 2.73 x |
| EV / Revenue | 14.2 x | 6.33 x | 5.04 x | 2.57 x | 2.11 x | 1.77 x |
| EV / EBITDA | 104 x | 49 x | 71.2 x | 25 x | 14.4 x | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 5.37 x | 3.25 x | 3.03 x | 1.77 x | 1.67 x | 1.51 x |
| Nbr of stocks (in thousands) | 133,726 | 134,853 | 135,549 | 131,264 | - | - |
| Reference price 2 | 16.32 | 10.21 | 9.120 | 5.760 | 5.760 | 5.760 |
| Announcement Date | 2/23/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 128 | 164 | 193.4 | 207.9 | 247.2 | 277 |
| EBITDA 1 | - | 17.52 | 21.17 | 13.7 | 21.43 | 36.17 | - |
| EBIT 1 | - | 16.66 | -1.804 | -26.78 | -17.39 | -3.748 | 9.692 |
| Operating Margin | - | 13.02% | -1.1% | -13.85% | -8.36% | -1.52% | 3.5% |
| Earnings before Tax (EBT) 1 | - | 5.948 | 1.26 | -14.64 | -10.43 | 7.849 | 23.64 |
| Net income 1 | 19.41 | 4.443 | 2.576 | -11.33 | -9.921 | 7.518 | 18.91 |
| Net margin | - | 3.47% | 1.57% | -5.86% | -4.77% | 3.04% | 6.83% |
| EPS 2 | - | 0.0500 | 0.0200 | -0.0900 | -0.0360 | 0.0880 | 0.1400 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 7/2/21 | 2/23/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 34.38 | 38.9 | 35.06 | 40.16 | 40.48 | 48.3 | 37.09 | 49.69 | 48 | 58.6 | 43.59 | 49.34 | 52.31 | 62.41 | 51.78 |
| EBITDA 1 | - | - | - | - | - | - | - | 1.542 | 3.72 | 10.96 | 1.589 | 3.31 | 4.913 | 11.56 | 4.158 |
| EBIT 1 | 3.072 | 5.238 | -2.357 | -0.891 | 1.36 | 0.084 | -12.16 | -9.127 | 1.159 | 0.932 | -9.202 | -6.289 | -4.289 | 1.483 | -7.152 |
| Operating Margin | 8.94% | 13.47% | -6.72% | -2.22% | 3.36% | 0.17% | -32.79% | -18.37% | 2.41% | 1.59% | -21.11% | -12.75% | -8.2% | 2.38% | -13.81% |
| Earnings before Tax (EBT) 1 | - | 0.454 | -3.303 | -1.401 | 1.85 | 4.114 | -9.04 | -6.595 | -4.185 | 5.18 | -6.995 | -4.305 | -2.405 | 4.553 | -4.643 |
| Net income 1 | - | 0.225 | -2.021 | -0.598 | 1.666 | 3.529 | -6.807 | -4.388 | -6.456 | 6.322 | -6.987 | -4.158 | -2.076 | 4.779 | -4.474 |
| Net margin | - | 0.58% | -5.76% | -1.49% | 4.12% | 7.31% | -18.35% | -8.83% | -13.45% | 10.79% | -16.03% | -8.43% | -3.97% | 7.66% | -8.64% |
| EPS 2 | - | 0.001700 | -0.0200 | - | 0.0100 | 0.0300 | -0.0500 | -0.0300 | -0.0500 | 0.0400 | -0.0500 | -0.0275 | -0.0125 | 0.0325 | -0.0333 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 2/23/22 | 5/11/22 | 8/10/22 | 11/9/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/7/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 365 | 339 | 261 | 221 | 235 | 266 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 6% | 5.02% | 2.01% | 0.12% | 5.03% | 10.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 3.040 | 3.140 | 3.010 | 3.260 | 3.440 | 3.820 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | 4.65 | - | - | - |
| Capex / Sales | - | - | - | 2.4% | - | - | - |
| Announcement Date | 7/2/21 | 2/23/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
5.76
USD
Average target price
10
USD
Spread / Average Target
+73.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.84% | 756M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- CTKB Stock
- Financials Cytek Biosciences, Inc.
